|Articles|March 16, 2021
HIC Analysis of Drug-to-Antibody Ratio
Author(s)Agilent Technologies, Inc.
This application note demonstrates the DAR determination of brentuximab vedotin using HIC. Excellent reproducibility was found with the Agilent 1290 Infinity II Bio LC.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
2
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5